Journal Menu
► ▼ Journal MenuJournal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
- Vol. 42 (2021)
- Vol. 41 (2021)
- Vol. 40 (2021)
- Vol. 39 (2020)
- Vol. 38 (2020)
- Vol. 37 (2020)
- Vol. 36 (2020)
- Vol. 35 (2020)
- Vol. 34 (2019)
- Vol. 33 (2019)
- Vol. 32 (2019)
- Vol. 31 (2019)
- Vol. 30 (2019)
- Vol. 29 (2018)
- Vol. 28 (2018)
- Vol. 27 (2018)
- Vol. 26 (2018)
- Vol. 25 (2018)
- Vol. 24 (2017)
- Vol. 23 (2017)
- Vol. 22 (2017)
- Vol. 21 (2017)
- Vol. 20 (2016)
- Vol. 19 (2016)
- Vol. 18 (2016)
- Vol. 17 (2015)
- Vol. 16 (2014)
- Vol. 15 (2013)
- Vol. 14 (2012)
- Vol. 13 (2011)
- Vol. 12 (2010)
- Vol. 11 (2009)
- Vol. 10 (2008)
- Vol. 9 (2007)
- Vol. 8 (2006)
- Vol. 7 (2005)
- Vol. 6 (2004)
- Vol. 5 (2003)
- Vol. 4 (2002)
- Vol. 3 (2001)
- Vol. 2 (2000)
- Vol. 1 (1999)
Need Help?
Curr. Issues Mol. Biol., Volume 46, Issue 4 (April 2024) – 59 articles
Cover Story (view full-size image):
Major tumor-suppressor genes such as TP53, CDKN2A and SMAD4 have been associated with pancreatic cancer. Each gene’s role, prevalence and impact on tumor development and progression are analyzed, focusing on the intricate molecular landscape of pancreatic cancer. Their prognostic significance seems promising. Potential targeted therapies tailored to these molecular signatures are under investigation. Literature findings highlight the importance of genomic analyses for risk assessment, early detection and the design of personalized treatment approaches in pancreatic cancer. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Previous Issue
Next Issue
Issue View Metrics
Multiple requests from the same IP address are counted as one view.